Drugs / Tilpisertib Fosmecarbil
Tilpisertib Fosmecarbil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06029972 | Dec 2023 → Jan 2027 expected | ulcerative colitis | Gilead Sciences | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tilpisertib Fosmecarbil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06029972 ↗ |
| Known as | Gs 5290 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067963 ↗ |
| Known as | Tilpisertib fosmecarbilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067963 ↗ |
| Modality | Small molecule | — CHEMBL6067963 ↗ |
| Route | Oral | “Tablets administered orally” NCT06029972 ↗ |